DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Letermovir
Letermovir
COMMISSION DE LA TRANSPARENCE Avis 5 Septembre 2018
Subtherapeutic Posaconazole Prophylaxis in a Gastric Bypass Patient Following Hematopoietic Stem Cell Transplantation
R&D Briefing 76
11-2018 BMT Pharmacists Johnson FINAL 2 12 18
Hinge Region in DNA Packaging Terminase Pul15 of Herpes Simplex Virus: a Potential Allosteric Target for Antiviral Drugs
Where Do We Stand After Decades of Studying Human Cytomegalovirus?
List of Drugs Not Repackaged by Safecor Health
Human Cytomegalovirus Primary Infection and Reactivation: Insights from Virion-Carried Molecules
Innovationsreport 2019 Kurzfassung
Letermovir for the Prevention of Cytomegalovirus Infection in Sero-Positive Patients Undergoing Allogeneic Haematopoietic Stem Cell Transplantation
PREVYMIS, Through the Centralised Procedure Falling Within the Article 3(1) and Point 4 of Annex of Regulation (EC) No 726/2004
PREVYMIS, INN-Letermovir
209939Orig1s000 209940Orig1s000
PREVYMIS™ (Letermovir) Oral
Long-Term Follow-Up After Hematopoietic Stem Cell Transplant General Guidelines for Referring Physician
Prevymis Tab Inj
The Third International Consensus Guidelinesthe on Management of Cytomegalovirus in Cincinnati, OH
Prevention and Treatment of Cancer-Related Infections
Top View
7. Post-Transplant Infection Considerations
ESAC-Net Reporting Protocol 2019.Docx
Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017
9. Antimicrobial Prophylaxis in HSCT-Patients: Guidelines and Evidence
Longitudinal Analysis of the Utility of Liver Biochemistry in Hospitalised COVID-19 Patients As Prognostic Markers
Management of CMV Reactivation and Infection in Bone Marrow
The Human Cytomegalovirus Terminase Complex As an Antiviral Target: a Close-Up View G
July August 2018 Clinical Rx Forum Newsletter.Pub
Year in Clinical Microbiology
Letermovir Guideline
Identification of a Short Sequence in the HCMV Terminase Pul56 Essential for Interaction with Pul89 Subunit G
Fast Breakthrough of Resistant Cytomegalovirus During Secondary Letermovir Prophylaxis in a Hematopoietic Stem Cell Transplant R
Use of Letermovir As Salvage Therapy for Drug-Resistant CMV Retinitis: a Case Series
Letermovir Protocol
Letermovir for Preventing Cytomegalovirus Disease After a Stem Cell Transplant
209939Orig1s000 209940Orig1s000
Letermovir (Prevymis™) 1.866.399.0928 (PLEASE PRINT – ACCURACY IS IMPORTANT) IA Medicaid Member ID # Patient Name DOB
Medication Guidelines for Solid Organ Transplants
Approved Antiviral Drugs Over the Past 50 Years
New Zealand Data Sheet 1 Product Name 2 Qualitative and Quantitative Composition 3 Pharmaceutical Form 4 Clinical Particulars 4
Guide to Antimicrobial Chemotherapy (PDF)
Prescription Drug Formulary
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: a Matched Cohort Study
Reimbursement Criteria for Frequently Requested Drugs
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
State and Specialty Pharmacy Drug Reimbursement Rates
Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2019
CENTENE PHARMACY and THERAPEUTICS DRUG REVIEW 1Q18 January – February BRAND NAME Prevymistm GENERIC NAME Letermovir MANUFACTU
Letermovir (Prevymis ®) : RMP Summary
Final Scheduling Decisions and Reasons
New Brunswick Drug Plans Formulary
Prevymis (Letermovir)
209939Orig1s000 209940Orig1s000
Human Cytomegalovirus Infection: a Considerable Issue Following Allogeneic Hematopoietic Stem Cell Transplantation (Review)
Specialty Drug List
Management of Herpesvirus Infections in Hematopoietic Cell Transplant Recipients
Letermovir for the Prophylaxis of Cytomegalovirus Reactivation Or Disease in People with Seropositive-Cytomegalovirus Who Have H
Merck Receives FDA Approval of PREVYMIS™ (Letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
Patented Medicine Prices Review Board
Letermovir 240Mg Film-Coated Tablets (Prevymis®) SMC No 1338/18 Merck Sharp and Dohme Ltd
Letermovir Salvage for Complicated Cases of Resistant
Updates (As of MAY 2021)
Specialty Drug List
Report on the Deliberation Results March 8, 2018 Pharmaceutical
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Medimpact April 2019 Specialty Drug List
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use PREVYMIS Safely and Effe
Do Not Tube List
Annual Report 2019
Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
Tenofovir Alafenamide
The Use of Antimalarial Drugs Against Viral Infection
Infection Prophylaxis and Treatment for Adult and Pediatric Bone Marrow Transplant Recipients
Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses
Association Between Antiviral Prophylaxis and Cytomegalovirus and Epstein–Barr Virus Dnaemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant
HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use PREVYMIS Safely and Effe
Letermovir (PREVYMIS)
PREVYMIS™ (Letermovir) Tablets, for Oral Use Drugs